智通财经APP讯，联影医疗(688271.SH)发布公告，公司员工持股平台持有的公司股份为首次公开发行 前公司实施的员工股权激励，员工持股平台持有人为800余名公司员工。因部分员工提出所持员工持股 计划份额所对应的公司股份出售申请(以下简称"出售申请")，员工持股平台拟通过大宗交易或集中竞价 (含盘后固定价格交易，下同)方式合计减持联影医疗股份不超过1337.66万股，合计不超过联影医疗总股 份的1.6231%。 ...

人民财讯8月3日电，联影医疗(688271)8月3日晚间公告，因部分员工提出所持员工持股计划份额所对应 的公司股份出售申请(简称"出售申请")，员工持股平台拟通过大宗交易或集中竞价(含盘后固定价格交 易)方式合计减持联影医疗股份不超过1337.66万股，合计不超过联影医疗总股份的1.6231%。 ...

格隆汇8月3日｜联影医疗(688271.SH)公告称，公司员工持股平台宁波影聚、宁波影力、宁波影健、宁 波影康、上海影董因部分员工提出出售申请，拟通过大宗交易或集中竞价方式合计减持公司股份不超过 13,376,600股，合计不超过公司总股份的1.6231%。减持价格参考市场价格，减持期间为2025年8月25日 至2025年11月24日。 ...

上述股份系其在首次公开发行前取得的股份，已于 2023 年 8 月 22 日起上市 流通。 减持计划的主要内容 证券代码：688271 证券简称：联影医疗 公告编号：2025-030 上海联影医疗科技股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持股的基本情况 本次减持计划实施前，上海联影医疗科技股份有限公司（以下简称"公司" 或"联影医疗"）股东宁波梅山保税港区影聚投资管理合伙企业（有限合伙）（以 下简称"宁波影聚"）持有公司股份 11,145,243 股，占公司总股本的 1.35%；宁 波梅山保税港区影力投资管理合伙企业（有限合伙）（以下简称"宁波影力"）持 有公司股份 12,411,182 股，占公司总股本的 1.51%；宁波梅山保税港区影健投 资管理合伙企业（有限合伙）（以下简称"宁波影健"）持有公司股份 12,411,182 股，占公司总股本的 1.51%；宁波梅山保税港区影康投资管理合伙企业（有限合 伙）（以下简称"宁波影康"）持有公司股份 ...

联影医疗公告，宁波影聚、宁波影力、宁波影健、宁波影康、上海影董等员工持股平台合计持股 5458.44万股，占6.62%。因员工出售申请，计划2025年8月25日至2025年11月24日期间，通过集中竞价 减持不超过824.14万股，大宗交易减持不超过1337.66万股，合计不超过1337.66万股，占1.6231%，股份 来源为IPO前取得。 ...

融券方面，当日融券卖出0.00万股，净买入0.79万股。 来源：金融界 最近三个交易日，30日-1日，联影医疗分别获融资买入0.22亿元、0.20亿元、0.14亿元。 8月1日，沪深两融数据显示，联影医疗获融资买入额0.14亿元，居两市第950位，当日融资偿还额0.18亿 元，净卖出423.93万元。 ...

Core Viewpoint - The China Securities Index for Healthcare Equipment and Services has shown positive performance, with a recent increase in its index value, indicating a growing interest and investment in the healthcare sector [1][2]. Group 1: Index Performance - The Shanghai Composite Index decreased by 0.37%, while the China Securities Index for Healthcare Equipment and Services rose by 0.47%, closing at 14,515.51 points with a trading volume of 28.859 billion [1]. - Over the past month, the China Securities Index for Healthcare Equipment and Services has increased by 6.65%, by 10.76% over the last three months, and by 6.04% year-to-date [1]. Group 2: Index Composition - The index is composed of listed companies in the healthcare sector, reflecting the overall performance of these companies [1]. - The top ten weighted companies in the index include: Mindray Medical (9.14%), United Imaging (8.05%), Aier Eye Hospital (7.32%), Aimeike (3.41%), Huatai Medical (2.89%), New Industry (2.6%), Yuyue Medical (2.57%), Lepu Medical (2.52%), Yingke Medical (2.06%), and Meinian Health (2.0%) [1]. - The index's holdings are primarily listed on the Shenzhen Stock Exchange (59.97%) and the Shanghai Stock Exchange (40.03%) [1]. Group 3: Industry Focus - The index exclusively represents the healthcare sector, with a 100% allocation to pharmaceutical and healthcare industries [2]. - The index samples are adjusted biannually, with changes implemented on the next trading day following the second Friday of June and December [2]. - Public funds tracking the healthcare index include various funds from Southern Fund, Tianhong Fund, and others, indicating a robust interest in this sector [2].

Core Insights - The Shanghai Composite Index decreased by 0.37%, while the CSI Hong Kong-Shanghai-Shenzhen 500 Healthcare Index fell by 1.74%, closing at 8507.96 points with a trading volume of 40.594 billion yuan [1] - Over the past month, the CSI Hong Kong-Shanghai-Shenzhen 500 Healthcare Index has increased by 17.84%, 24.27% over the last three months, and 34.48% year-to-date [1] Index Composition - The CSI Hong Kong-Shanghai-Shenzhen 500 Healthcare Index is composed of 11 industry categories, reflecting the overall performance of different sectors within the index [1] - The top ten holdings in the index are: WuXi AppTec (10.42%), Hengrui Medicine (9.97%), BeiGene (9.63%), Innovent Biologics (6.64%), Mindray Medical (6.06%), WuXi Biologics (5.19%), CanSino Biologics (4.4%), China National Pharmaceutical Group (3.36%), CSPC Pharmaceutical Group (3.17%), and United Imaging Healthcare (2.85%) [1] Market Distribution - The market distribution of the CSI Hong Kong-Shanghai-Shenzhen 500 Healthcare Index shows that the Hong Kong Stock Exchange accounts for 37.87%, the Shanghai Stock Exchange for 33.61%, and the Shenzhen Stock Exchange for 28.52% [2] Sector Allocation - The sector allocation within the index includes: Chemical Drugs (36.20%), Pharmaceutical and Biotechnology Services (18.33%), Biopharmaceuticals (18.14%), Medical Devices (11.07%), Traditional Chinese Medicine (8.56%), and Medical Commerce and Services (7.70%) [2] Index Adjustment - The index samples are adjusted biannually, with adjustments occurring on the next trading day following the second Friday of June and December each year [2] - Weight factors are generally fixed until the next scheduled adjustment, with special circumstances allowing for temporary adjustments [2] Fund Tracking - Public funds tracking the CSI Hong Kong-Shanghai-Shenzhen 500 Healthcare Index include the China Merchants CSI Hong Kong-Shanghai-Shenzhen 500 Healthcare ETF [3]

Group 1 - The core viewpoint highlights the active trading and significant growth of the Science and Technology Innovation (Sci-Tech) Pharmaceutical ETF managed by Harvest, with a turnover rate of 21.72% and a transaction volume of 47.63 million yuan on July 31 [2] - Over the past week, the Sci-Tech Pharmaceutical ETF has seen an average daily transaction volume of 53.21 million yuan, ranking first among comparable funds [2] - The fund's scale increased by 16.78 million yuan in the past week, also leading among comparable funds, with a share increase of 12.50 million shares [2] Group 2 - The fund has attracted a total of 14.72 million yuan in inflows over the last five trading days [2] - As of July 31, the net value of the Sci-Tech Pharmaceutical ETF has risen by 48.77% over the past year, ranking 350 out of 2943 in the index stock fund category, placing it in the top 11.89% [2] - The fund's highest monthly return since inception was 23.29%, with the longest consecutive monthly gain being six months and a maximum increase of 41.76% [2] Group 3 - The top ten weighted stocks in the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index account for 49.14% of the index, with leading companies including United Imaging Healthcare and BeiGene [2] - The stock performance of the top ten companies shows mixed results, with some stocks experiencing slight declines while others have positive growth [4] Group 4 - The National Healthcare Security Administration has established a "new drug first launch price mechanism" to encourage drug research and innovation, marking a significant policy development [4] - The pharmaceutical and biotech sectors are expected to benefit from a high level of innovation and a potential revaluation of value stocks, with recommendations for companies in the Pharma and Biopharma/Biotech sectors [5] - The medical device industry is also anticipated to benefit from policy optimizations, with recent statements from relevant authorities supporting innovation and addressing issues of internal competition [5]

7月31日，沪深两融数据显示，联影医疗获融资买入额0.20亿元，居两市第951位，当日融资偿还额0.31 亿元，净卖出1156.13万元。 融券方面，当日融券卖出0.03万股，净买入0.66万股。 来源：金融界 最近三个交易日，29日-31日，联影医疗分别获融资买入0.31亿元、0.22亿元、0.20亿元。 ...